XNASPMN
Market cap30mUSD
Dec 23, Last price
0.92USD
1D
0.00%
1Q
-29.23%
IPO
-92.31%
Name
ProMIS Neurosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.26%
Rev. gr., 5y
-29.29%
Revenues
0k
Net income
-18m
L+37.36%
CFO
-14m
L-15.65%
Earnings
May 12, 2025
Profile
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 24,708 | 45,161 | 14,114 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (24,708) | (45,161) | (14,114) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (168) | (5,318) | 415 | ||||||
Tax Rate | |||||||||
NOPAT | (24,540) | (39,843) | (14,529) | ||||||
Net income | (17,506) 37.36% | (12,745) | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,974 | 20,017 | |||||||
BB yield | -15.28% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 4,939 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 684 | 1,859 | 9,170 | ||||||
Net debt | (16,754) | (8,015) | (16,537) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (14,368) | (17,034) | |||||||
CAPEX | (2) | ||||||||
Cash from investing activities | (2) | 94 | |||||||
Cash from financing activities | 23,517 | 6,495 | 25,202 | ||||||
FCF | (24,540) | (39,843) | (15,590) | ||||||
| Balance | |||||||||
Cash | 16,754 | 8,015 | 21,477 | ||||||
Long term investments | |||||||||
Excess cash | 16,754 | 8,015 | 21,477 | ||||||
Stockholders' equity | (123,839) | (108,659) | (22,137) | ||||||
Invested Capital | 128,812 | 106,834 | 43,404 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 12,293 | 7,503 | 5,786 | ||||||
Price | 1.15 -73.50% | 4.34 | |||||||
Market cap | 14,137 -56.58% | 32,561 | |||||||
EV | (2,617) | 24,546 | |||||||
EBITDA | (3,549) | (45,150) | (14,068) | ||||||
EV/EBITDA | 0.74 | ||||||||
Interest | 201 | 282 | 415 | ||||||
Interest/NOPBT | |||||||||